Rockefeller Capital Management L.P. Buys Shares of 177,377 Immuneering Co. (NASDAQ:IMRX)

Rockefeller Capital Management L.P. acquired a new stake in Immuneering Co. (NASDAQ:IMRX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 177,377 shares of the company's stock, valued at approximately $390,000. Rockefeller Capital Management L.P. owned about 0.57% of Immuneering as of its most recent SEC filing.

Separately, HighTower Advisors LLC raised its position in Immuneering by 21.4% during the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company's stock valued at $132,000 after purchasing an additional 9,400 shares in the last quarter. Hedge funds and other institutional investors own 67.65% of the company's stock.

Immuneering Stock Performance

Shares of NASDAQ:IMRX traded down $0.01 during midday trading on Friday, reaching $1.45. 47,041 shares of the company's stock traded hands, compared to its average volume of 2,353,456. The company has a fifty day simple moving average of $1.51 and a two-hundred day simple moving average of $1.85. Immuneering Co. has a 1 year low of $1.00 and a 1 year high of $3.83. The company has a market cap of $52.18 million, a P/E ratio of -0.74 and a beta of -0.25.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its earnings results on Thursday, March 20th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.16). As a group, research analysts forecast that Immuneering Co. will post -1.86 EPS for the current fiscal year.

Analyst Ratings Changes

IMRX has been the topic of several research analyst reports. Chardan Capital reiterated a "buy" rating and set a $13.00 price target on shares of Immuneering in a research note on Monday, March 24th. Needham & Company LLC reissued a "buy" rating and set a $12.00 price target on shares of Immuneering in a report on Thursday, April 10th.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.